Icon (ICLR) Projected to Post Quarterly Earnings on Wednesday
by Scott Moore · The Cerbat GemIcon (NASDAQ:ICLR – Get Free Report) is projected to release its Q4 2025 results after the market closes on Wednesday, April 29th. Analysts expect Icon to post earnings of $3.02 per share and revenue of $1.9701 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:00 PM ET.
Icon Stock Up 1.0%
Shares of Icon stock opened at $103.21 on Tuesday. Icon has a 12-month low of $66.57 and a 12-month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a 50 day moving average price of $105.94 and a two-hundred day moving average price of $150.24. The stock has a market capitalization of $8.34 billion, a P/E ratio of 13.97, a PEG ratio of 2.59 and a beta of 1.28.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in shares of Icon in the second quarter valued at about $254,000. Daiwa Securities Group Inc. increased its stake in Icon by 19.3% during the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after acquiring an additional 4,546 shares during the period. Frontier Capital Management Co. LLC increased its stake in Icon by 97.6% during the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after acquiring an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new position in Icon in the 2nd quarter valued at approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after acquiring an additional 289 shares during the period. Institutional investors own 95.61% of the company’s stock.
Wall Street Analysts Forecast Growth
ICLR has been the subject of several recent analyst reports. Bank of America reaffirmed an “underperform” rating and set a $75.00 price objective on shares of Icon in a report on Thursday, February 12th. Truist Financial reiterated a “hold” rating and issued a $222.00 target price (down from $231.00) on shares of Icon in a report on Thursday, January 8th. Robert W. Baird set a $119.00 price target on shares of Icon in a report on Friday, February 13th. Citigroup lowered their price target on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Finally, BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $100.00 to $130.00 in a research note on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus target price of $148.80.
Read Our Latest Stock Analysis on Icon
About Icon
Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.
Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.